0
16/7 2021 15:46 Aps invest 095249 Jep, forpestet af shorting....nu 2,58% .... Hader det pengegriske skidt
16/7 2021 13:32 Makingmoney 195242 Hansa nok dette som har givet kursfaldet progress and outlook remain most important for Hansa. In the GBS (Guillain-Barré syndrome) trial, 10 out of 30 patients are now enrolled (8 at the earlier Q1), and in the important, (complements Ideflirix) AMR (Antibody-mediated kidney transplant rejection) trial, 12 out of 30 patients are now enrolled (9 at the earlier Q1). The enrolment rate appears to be modest, especially as Hansa's earlier communication is that both studies are expected to be fully enrolled during H2 2021, and this is now modified to H2 2021/H2 2022.
Vi
Morten
Vi
Morten
